Open access
Open access
Powered by Google Translator Translator

Covid-19

Underlying medical conditions associated with severe COVID-19 illness among children – the strongest risk factors for hospitalization were chronic and complex chronic diseases, type 1 diabetes, and obesity.

8 Jun, 2021 | 09:37h | UTC

Underlying Medical Conditions Associated With Severe COVID-19 Illness Among Children – JAMA Network Open

Commentaries: Underlying illness, respiratory infection raise risk for severe COVID in kids – CIDRAP AND COVID-19 in Children—Not Just Little Adults – JAMA Network Open

 

Commentary on Twitter

 


Are SARS-CoV-2 Human Challenge Trials Ethical? – “A clinical trial is underway in the UK in which young, healthy participants are exposed deliberately to SARS-CoV-2 to assess the viral inoculum needed to produce an infection and to test vaccine efficacy”.

8 Jun, 2021 | 09:29h | UTC

Are SARS-CoV-2 Human Challenge Trials Ethical? – JAMA Internal Medicine

Related: World’s first coronavirus “Human Challenge” study receives ethics approval in the UK (several texts on the subject)

 

Commentary on Twitter

 


The “Black Fungus” in India: The Emerging Syndemic of COVID-19–Associated Mucormycosis – careful use of antibiotics and corticosteroids and closely monitoring blood glucose levels are some of the strategies suggested by the authors.

8 Jun, 2021 | 09:34h | UTC

The “Black Fungus” in India: The Emerging Syndemic of COVID-19–Associated Mucormycosis – Annals of Internal Medicine

 


Multicenter Epidemiologic Study of Coronavirus Disease–Associated Mucormycosis, India – Uncontrolled diabetes mellitus was the most common underlying disease; improper glucocorticoid use was independently associated with the disease.

8 Jun, 2021 | 09:33h | UTC

Multicenter Epidemiologic Study of Coronavirus Disease–Associated Mucormycosis, India – CDC Emerging Infectious Diseases

Commentary: COVID19: Secondary Infections Still a Big Challenge in India – News Click

 

Commentary on Twitter

 


Report: 376,000 people in UK have had long Covid symptoms for at least a year.

8 Jun, 2021 | 09:27h | UTC

376,000 people in UK have had long Covid symptoms for at least a year – ONS – The Guardian

Original report: Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 4 June 2021 – Office for National Statistics

 


Practice Pointer | Mask related acne (“maskne”) and other facial dermatoses.

8 Jun, 2021 | 09:24h | UTC

Mask related acne (“maskne”) and other facial dermatoses – The BMJ

 

Commentary on Twitter

 


Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection – there was a significant association between skin rashes and a positive swab test result (odds ratio 1.67).

8 Jun, 2021 | 09:26h | UTC

Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection – British Journal of Dermatology

 


RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.

7 Jun, 2021 | 00:01h | UTC

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial – The Lancet

Related: #ACC21 – [Not published yet] RCT: Among hospitalized patients with Covid-19 and elevated D-Dimer, therapeutic anticoagulation with Rivaroxaban 20 mg was not associated with improved outcomes and resulted in increased major bleeding.

 

Commentary on Twitter

https://twitter.com/RenatoDLopes1/status/1400962037610582026

 


Six months of COVID vaccines: what 1.7 billion doses have taught scientists.

6 Jun, 2021 | 23:57h | UTC

Six months of COVID vaccines: what 1.7 billion doses have taught scientists – Nature

See also: Coronavirus (COVID-19) Vaccinations – Our World in Data

 

Related commentary on Twitter

 


WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic.

6 Jun, 2021 | 23:56h | UTC

WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic – Nature

Related: WHO validates Sinovac-CoronaVac COVID-19 vaccine for emergency use and issues interim policy recommendations. AND Brazilian town experiment shows mass vaccination can wipe out COVID-19.

 


Study shows reduced neutralizing antibody activity induced by Pfizer–BioNTech vaccine against SARS-CoV-2 variants of concern B.1.617.2 (Delta) and B.1.351 (Beta).

6 Jun, 2021 | 23:59h | UTC

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2  and B.1.351 (Beta) by BNT162b2 vaccination – The Lancet

Commentary: Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant – The Francis Crick Institute

 

Commentary on Twitter (thread – click for more)

 


Case report: Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT).

6 Jun, 2021 | 23:55h | UTC

Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT) – Journal of Thrombosis and Haemostasis

Commentary: COVID-19 vaccination: Thrombosis can be prevented by prompt treatment, researchers report – Medical University of Vienna

 


More data on the harmful effects of the COVID-19 pandemic on the mental health of adolescents.

6 Jun, 2021 | 23:52h | UTC

Depressive symptoms, mental wellbeing, and substance use among adolescents before and during the COVID-19 pandemic in Iceland: a longitudinal, population-based study – The Lancet Psychiatry

Commentaries: A lost generation? COVID-19 and adolescent mental health – The Lancet Psychiatry AND COVID-19 pandemic has had significant impact on the mental health of adolescents – Columbia University Mailman School of Public Health

 

Commentary on Twitter (thread – click for more)

https://twitter.com/TheLancetPsych/status/1400783180937011202

 


2 new meta-analysis detail neurologic and psychiatric conditions in COVID-19.

6 Jun, 2021 | 23:54h | UTC

Neurologic, psychiatric conditions common in COVID-19 – CIDRAP

Meta-analysis 1: Neurology and neuropsychiatry of COVID-19: a systematic review and meta-analysis of the early literature reveals frequent CNS manifestations and key emerging narratives – Journal of Neurology, Neurosurgery & Psychiatry

Meta-analysis 2: Central and peripheral nervous system involvement by COVID-19: a systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings – BMC Infectious Diseases

Related: Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions

 


Perspective | Could statins do more than lower cholesterol in patients with COVID-19? – “Don’t Start, Don’t Stop”.

6 Jun, 2021 | 23:49h | UTC

Could Statins Do More Than Lower Cholesterol in Patients With COVID-19? – JAMA

 


Opinion | “Doctors have been blamed for the rise in black fungus in India, but the COVID treatment guidelines could be contributing” – improper use of antibiotics and higher than usual doses of corticosteroids may be contributing to the emergence of mucormycosis and other fungal co-infections.

6 Jun, 2021 | 23:48h | UTC

Doctors have been blamed for the rise in black fungus in India, but the COVID treatment guidelines could be contributing – The Conversation

See also: Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? – The Lancet Respiratory Medicine

Related: The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries – The Lancet AND What Is ‘Black Fungus’? And Why Is It Spreading Among India’s COVID Patients? – NPR AND Mucormycosis: The ‘black fungus’ maiming Covid patients in India AND What is mucormycosis, the fungal infection affecting COVID patients in India? – The Conversation

 


Investigation | Covid 19: How harm reduction advocates and the tobacco industry capitalized on the pandemic to promote nicotine.

6 Jun, 2021 | 23:51h | UTC

Covid 19: How harm reduction advocates and the tobacco industry capitalised on the pandemic to promote nicotine – The BMJ

Commentaries: Researchers report how the tobacco and e-cigarette industry capitalized on COVID-19 to promote smoking – News Medical AND Investigation discredits studies suggesting lower COVID-19 risk for smokers

 


Another study shows a high frequency of antibiotic use among patients hospitalized with Covid-19 (85.2%), despite low rates of confirmed secondary bacterial infections.

4 Jun, 2021 | 10:43h | UTC

Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study – The Lancet Microbe

Commentaries: Very high use of antibiotics in COVID-19 treatment could be reduced – University of Glasgow AND More evidence of frequent antibiotic use noted in COVID patients – CIDRAP AND Covid-19: Antimicrobial use was high during first wave despite bacterial co-infections being rare, study finds – The BMJ

Related: Many hospitalized Covid-19 patients are given antibiotics. That’s a problem – STAT

 

Commentary on Twitter (thread – click for more)

 


In a Mendelian randomization study, researchers found no genetic evidence to support an association between Vitamin D levels and COVID-19 susceptibility, severity, or hospitalization.

4 Jun, 2021 | 10:35h | UTC

Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study – PLOS Medicine

Commentary: Vitamin D may not provide protection from COVID-19 susceptibility or disease severity, study suggests – PLOS

Related: Living systematic review: The evidence is insufficient to determine the benefits and harms of vitamin D supplementation as a treatment of COVID‐19. AND RCT: Vitamin D3 does not improve outcomes in hospitalized patients with moderate to severe COVID-19

 


RCT: Prophylactic post-exposure prophylaxis with Bamlanivimab reduced the incidence of Covid-19 among residents and staff of skilled nursing and assisted living facilities.

4 Jun, 2021 | 10:40h | UTC

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial – JAMA

Editorial: Bamlanivimab for Prevention of COVID-19

 


[Preprint] Covid-19 B.1.617.2 variant of concern (Delta) is associated with increased transmissibility compared to B.1.1.7 (Alpha) that will rapidly lead to B.1.617.2 becoming the prevailing variant in the UK.

4 Jun, 2021 | 10:36h | UTC

Interim estimates of increased transmissibility, growth rate, and reproduction number of the Covid-19 B.1.617.2 variant of concern in the United Kingdom – medRxiv

Related: Covid: Indian variant ‘now dominant’ in the UK – BBC

 


United States Unveils Global Vaccine Sharing Scheme for 80 Million Doses by End June

4 Jun, 2021 | 10:32h | UTC

BREAKING – United States Unveils Global Vaccine Sharing Scheme for 80 Million Doses by End June – Health Policy Watch

See also: Statement by President Joe Biden on Global Vaccine Distribution – The White House

 


WHO: Vaccinating kids ‘not a high priority’ amid shortage

4 Jun, 2021 | 10:31h | UTC

WHO: Vaccinating kids ‘not a high priority’ amid shortage – Associated Press

Related: WHO: Wealthy nations urged to delay youth Covid vaccines, donate to solidarity scheme AND Editorial: Vaccinating children against SARS-CoV-2 – “Hard to justify right now for most children in most countries”. AND Opinion | American Kids Can Wait – “The U.S. should delay shots for children until global vaccine-manufacturing capacity significantly expands and the crisis in India subsides”. AND Vaccinating children before poor morally wrong, Oxford scientist says – BBC

 


Countries hit hardest by COVID-19 – estimated mortality countries will have on September 1, 2021.

3 Jun, 2021 | 11:09h | UTC

Countries Hit Hardest by COVID-19 – Think Global Health

 

Commentary on Twitter (thread – click for more)

 


Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

3 Jun, 2021 | 11:06h | UTC

6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study – The Lancet Child & Adolescent Health

Commentary: Most severe effects of MIS-C in children typically resolve within six months, new research suggests – CNN AND Children who developed a rare inflammation disease after COVID-19 are mostly better after 6 months, but some still suffer fatigue and anxiety, a small UK study found – Insider AND Most severe effects of PIMS-TS resolved at six months – HealthDay

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.